Clinical Trial Update: A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years [Phase 2]

View source ↗

Summary

A Phase 2 trial of the chikungunya vaccine VLA1553 in healthy children aged 1 to 11 years has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• VLA1553

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Chikungunya Virus Infection | Phase 2 | Status: COMPLETED